Joint Clinical Assessment (JCA) Dossier Manager, International HTA Strategy

Benefits

Parental leave

12 weeks Verified - employer source source checked May 7, 2026

Non-birth-parent leave

12 weeks Verified - employer source source checked May 7, 2026

Family-building benefits

• Fertility benefits: Not verified
• Adoption assistance: Not verified
• Surrogacy assistance: Not verified

Mental health support

Not verified

Relocation assistance

Not verified

Childcare support

Not verified

Learning budget

Not verified

Verification

Source-linked checked May 7, 2026

Salary

Not verified

401(k) match

Reported from DOL Form 5500 industry filing (not employer-specific)

Was this benefit information wrong? Tell us.

Market context

U.S. role benchmark (BLS OEWS)

$102,662 U.S. median for this role

Projected growth (BLS Employment Projections)

+5.4% - Faster than average

Matched to SOC 11-1021 - Product Management aggregate by role bucket.

Source: U.S. Bureau of Labor Statistics, OEWS, May 2024 and Employment Projections, 2024-2034.

Schedule

Shift type

Not verified

Weekend work

Not verified

Company

Equity

Offered Verified - SEC 10-K source

Application

Cover letter

Not verified

Assessment

Not verified

Deadline

Not stated

Where they hire

State eligibility is not yet verified.

About this role

Joint Clinical Assessment (JCA) Dossier Manager, International HTA Strategy Paris, IDF, France Company Description: AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas - immunology, oncology, neuroscience, and eye care - and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com . Follow @abbvie on X , Facebook , Instagram , YouTube , LinkedIn and Tik Tok . Job Description: Advances in scientific and technological research are opening up new, promising treatments for previously difficult to treat diseases, increasing the demand on already constrained healthcare budgets. The challenging economic and political environment is leading Health Technology Assessment (HTA) agencies and payers to demand better outcomes at lower cost to overall health system. In 2021 European commission adopted the EU HTA regulation with the key objectives of accelerating patient access to innovative treatments by harmonizing methodologies, establishing predictability and avoiding duplications. For AbbVie, this provides a unique opportunity to demonstrate the value attributes of our assets & strengthen affiliate position in country P&R appraisals. Joint Clinical Assessments is the key component of the EU HTA regulation and comprises the EU HTA dossier that will need to be submitted to the Member State Coordination Group on HTA; eg, to address issues of relative effectiveness and relative safety within a single submission. For AbbVie,

Read the full description at jobs.smartrecruiters.com. FewerJobs shows a preview and links to the original posting.